Traders Purchase Large Volume of ImmunityBio Call Options (NASDAQ:IBRX)

ImmunityBio, Inc. (NASDAQ:IBRX) was the recipient of unusually large options trading on Tuesday. Stock investors purchased 23,649 call options on the stock. This is an increase of approximately 308% compared to the typical volume of 5,801 call options.

Institutional Trading of ImmunityBio

Several large investors have recently bought and sold shares of the company. Traynor Capital Management Inc. bought a new stake in shares of ImmunityBio in the 3rd quarter worth approximately $25,000. Aire Advisors LLC bought a new position in ImmunityBio in the 3rd quarter valued at approximately $25,000. WINTON GROUP Ltd bought a new position in ImmunityBio in the 3rd quarter valued at approximately $26,000. Vanguard Personalized Indexing Management LLC bought a new position in ImmunityBio in the 3rd quarter valued at approximately $37,000. Finally, Meridian Management Co. bought a new position in ImmunityBio in the 4th quarter valued at approximately $46,000. 8.58% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Piper Sandler lifted their price objective on ImmunityBio from $4.00 to $5.00 and gave the stock a “neutral” rating in a report on Monday, March 25th.

ImmunityBio Trading Down 12.2 %

IBRX opened at $4.82 on Thursday. ImmunityBio has a 12 month low of $1.25 and a 12 month high of $6.93. The company has a market cap of $3.26 billion, a P/E ratio of -4.16 and a beta of 1.23. The business’s 50-day moving average price is $5.20 and its 200-day moving average price is $4.14.

ImmunityBio (NASDAQ:IBRX) last announced its quarterly earnings results on Tuesday, March 19th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01). The company had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.03 million. Equities research analysts forecast that ImmunityBio will post -0.68 earnings per share for the current fiscal year.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies.